1. Home
  2. SWAG vs BOLT Comparison

SWAG vs BOLT Comparison

Compare SWAG & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWAG
  • BOLT
  • Stock Information
  • Founded
  • SWAG 1994
  • BOLT 2015
  • Country
  • SWAG United States
  • BOLT United States
  • Employees
  • SWAG N/A
  • BOLT N/A
  • Industry
  • SWAG Advertising
  • BOLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SWAG Consumer Discretionary
  • BOLT Health Care
  • Exchange
  • SWAG Nasdaq
  • BOLT Nasdaq
  • Market Cap
  • SWAG N/A
  • BOLT 16.8M
  • IPO Year
  • SWAG 2021
  • BOLT 2021
  • Fundamental
  • Price
  • SWAG $1.06
  • BOLT $0.37
  • Analyst Decision
  • SWAG
  • BOLT Hold
  • Analyst Count
  • SWAG 0
  • BOLT 5
  • Target Price
  • SWAG N/A
  • BOLT $1.13
  • AVG Volume (30 Days)
  • SWAG 21.1K
  • BOLT 106.7K
  • Earning Date
  • SWAG 04-14-2025
  • BOLT 05-13-2025
  • Dividend Yield
  • SWAG N/A
  • BOLT N/A
  • EPS Growth
  • SWAG N/A
  • BOLT N/A
  • EPS
  • SWAG N/A
  • BOLT N/A
  • Revenue
  • SWAG $82,654,000.00
  • BOLT $7,690,000.00
  • Revenue This Year
  • SWAG N/A
  • BOLT N/A
  • Revenue Next Year
  • SWAG N/A
  • BOLT $77.48
  • P/E Ratio
  • SWAG N/A
  • BOLT N/A
  • Revenue Growth
  • SWAG 8.76
  • BOLT N/A
  • 52 Week Low
  • SWAG $0.73
  • BOLT $0.30
  • 52 Week High
  • SWAG $1.44
  • BOLT $1.34
  • Technical
  • Relative Strength Index (RSI)
  • SWAG 51.28
  • BOLT 50.57
  • Support Level
  • SWAG $1.00
  • BOLT $0.33
  • Resistance Level
  • SWAG $1.12
  • BOLT $0.38
  • Average True Range (ATR)
  • SWAG 0.07
  • BOLT 0.03
  • MACD
  • SWAG -0.01
  • BOLT 0.00
  • Stochastic Oscillator
  • SWAG 43.67
  • BOLT 50.00

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Share on Social Networks: